Filter results
You can narrow down the results using the filters
Audience
Topics
Our work
Year
2 results
-
Soliris® (eculizumab) available on PBS from 1 March 2022
The program that subsidises Soliris® for patients with a rare condition called paroxysmal nocturnal haemoglobinuria (PNH) is changing. Until now, we have subsidised Soliris® under the Life Saving Drugs Program. From 1 March 2022, this will change to the Pharmaceutical Benefits Scheme (PBS). -
Driving social inclusion through sport and physical activity
A new initiative will help migrant groups, people with physical and intellectual disabilities and Aboriginal and Torres Strait Islander peoples to participate in sport and physical activity.